Bexarotene

Bexarotene (Targretin, H.A.C. Pharma) has 1 EU-approved indication in 1 tumour type.
Approved indications of Bexarotene
Biomarker requirementRegimenSettingConditions
T-cell lymphoma1
None
Monotherapy
2L
advanced
Cutaneous T-cell lymphoma only; After at least one systemic treatment; Skin manifestations
Full text of section 4.1 (therapeutic indications)

Targretin is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) in adult patients refractory to at least one systemic treatment.

Label history

32 changes to the Targretin label since 2002, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes